Curis

• NCT04278768

  Phase 1/2, Suspended, 366 people, 20 Feb 2020

• CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

  Phase 1/2, Recruiting, 152 people, 1 Nov 2017

• NCT01742988

  Phase 1, Completed, 106 people, 6 Dec 2012

• NCT01384799

  Phase 1, Completed, 12 people, 29 Jun 2011

Sources: clinicaltrials.gov

• MON-524 The Impact of SGLT2 Inhibitors on Adverse Genitourinary Effects in Prostate Cancer Survivors With Diabetes

  ENDO 2025 abstract, 23 Oct 2025